Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus

Table 3 Suggested equivalent doses for different glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists based on their impact on glycemic control

Agent	Route	Frequency	Equivalent dose
Exenatide	SC	Twice daily	5 μg1	10 μg
Lixisenatide	SC	Daily	10 μg1	20 μg
Liraglutide	SC	Weekly	0.6 mg1	1.2 mg	1.8 mg
Exenatide XR	SC	Weekly			2 mg
Dulaglutide	SC	Weekly		0.75 mg1	1.5 mg	3 mg	4.5 mg
Semaglutide	SC	Weekly		0.25 mg1	0.5 mg		1 mg	2 mg
Semaglutide	PO	Daily	3 mg1	7 mg	14 mg
Tirzepatide	SC	Weekly			2.5 mg1			5 mg	7.5 mg	10 mg	12.5 mg	15 mg

¹The comparative efficacy of starting doses is not known and is based on the clinical experience of the authors in this group in various settings in different countries.

SC: Subcutaneous; PO: Oral.